Founded with the mission to revolutionize cancer treatment, Oncobox provides personalized genetic profiling to help doctors identify the most effective drugs for individual patients. The company focuses on late-stage cancer patients, aiming to reduce premature deaths by offering a data-driven tool that evaluates the molecular nuances of tumors. Oncobox Dx, their flagship product, assesses the effectiveness of 170 targeted and immunotherapy drugs, enabling healthcare providers to craft personalized treatment plans.

Notable affiliated people include leading cancer researchers from Europe and Asia who have validated Oncobox's approach through studies involving 900 patients with various late-stage cancers. The company has garnered attention for its low-cost, high-impact solution, significantly improving clinical outcomes. Oncobox's innovative approach has made a substantial impact on personalized cancer therapy, providing hope and more effective treatment options for patients worldwide.